封面
市場調查報告書
商品編碼
1585793

腦生物標記市場:按產品、適應症、最終用戶和應用 - 全球預測 2025-2030

Brain Biomarkers Market by Product (Biomarker Analyzers, Biomarker Test Kits), Indication (Alzheimer's Disease, Huntington's Disease, MND & ALS), End-Users, Application - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年,腦生物標記市場估值為89.4億美元,預計到2024年將達到105.4億美元,複合年成長率為17.90%,到2030年將達到283.3億美元。

大腦生物標記是大腦生物過程的可測量指標,通常用於評估神經系統狀況。它對於阿茲海默症、帕金森氏症和各種精神疾病的診斷和監測至關重要。這些生物標記的範圍從遺傳和蛋白質組到成像和生理訊號。對大腦生物標記的需求在於它們能夠促進早期診斷、追蹤疾病進展、制定個人化治療計劃以及顯著改善患者治療結果和醫療保健效率。

主要市場統計
基準年[2023] 89.4億美元
預測年份 [2024] 105.4億美元
預測年份 [2030] 283.3億美元
複合年成長率(%) 17.90%

大腦生物標記的應用涵蓋診斷、藥物開發和治療監測。它被醫院、研究機構和臨床實驗室僱用,為神經科、精神病學家和其他醫療保健專業人員提供服務。神經系統疾病的日益普及、個人化醫療需求的不斷成長以及生物標記技術的進步推動了大腦生物標記市場的發展。新的商機包括整合人工智慧和機器學習以增強生物標記的發現和分析,以及探索心理健康領域的生物標記。

關鍵的成長要素包括神經影像和基因組學的技術進步、對大腦健康意識的提高以及對精準醫療的投資增加。然而,生物標記發現和檢驗的高成本、監管的複雜性以及縱向資料的有限可用性等挑戰構成了主要障礙。此外,有關基因測試和資料隱私的道德考慮可能會影響市場動態。

需要開拓創新領域,例如檢測複雜生物標記的多組體學、開發非侵入性生物標記檢測方法以及生物技術公司和研究機構之間的合作以加速研發。更加重視整合患者特定資料以完善預測模型的個人化醫療方法預計將擴大市場。

總之,在技術進步和醫療保健需求的推動下,大腦生物標記市場已準備好成長。應對挑戰需要對研究進行策略性投資、跨學科合作、強大的監管環境來駕馭道德和技術環境,以及創新和擴大市場的新創新。

市場動態:揭示快速發展的大腦生物標記市場的關鍵市場洞察

供需的動態交互作用正在改變大腦生物標記市場。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,並了解消費行為及其對製造成本的影響,並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 研發投資旨在提高對神經系統疾病的了解並治療不斷成長的老年人群中的腦部疾病
    • 需要侵入性腦部測試、有效的藥物開發、快速診斷和新的治療選擇
    • 檢測和解釋以支持臨床決策和患者干涉
  • 市場限制因素
    • 缺乏消費者意識
  • 市場機會
    • 支持基於生物標記的藥物開發和轉化研究的生物標記資料管理平台的演變
    • 將可檢測參數納入大腦生物標記以改善臨床決策
  • 市場挑戰
    • 生物異質性進一步加劇了發炎的複雜性。

波特五力:駕馭腦部生物標記市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解大腦生物標記市場的外部影響

外部宏觀環境因素在塑造大腦生物標記市場的動態表現方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並幫助他們做出積極主動的決策。

市場佔有率分析 了解大腦生物標記市場的競爭狀況

對大腦生物標記物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣腦生物標記市場供應商的績效評估

FPNV定位矩陣是評估大腦生物標記市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商,從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商,以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了大腦生物標記市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說,對腦生物標記市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機,並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 研發投資旨在提高對神經系統疾病的了解並治療不斷成長的患有腦部疾病的老年人口
      • 需要侵入性腦部測試、有效的藥物開發、更快的診斷和新的治療選擇
      • 檢測和解釋以支持臨床決策和患者干涉
    • 抑制因素
      • 缺乏消費者意識
    • 機會
      • 不斷發展的生物標記資料管理平台,支援基於生物標記的藥物開發和轉化研究
      • 將可檢測參數納入大腦生物標記以改善臨床決策
    • 任務
      • 生物多樣性加劇了發炎的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腦生物標記市場:依產品

  • 生物標記分析儀
  • 生物標記檢測套組

第7章依適應症分類的腦生物標記市場

  • 阿茲海默症
  • 亨丁頓舞蹈症
  • 肌萎縮側索硬化症和肌萎縮側索硬化症
  • 帕金森氏症
  • 中風

第 8 章 腦生物標記市場:依最終用戶分類

  • 門診手術中心
  • 診斷實驗室
  • 醫院
  • 研究室

第9章腦生物標記市場:依應用分類

  • 診斷
  • 藥物發現與開發

第10章美洲腦生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區腦生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的腦生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Advanced Brain Monitoring, Inc
  • Biognosys AG
  • BrainScope Company, Inc.
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Johnson & Johnson
  • Lifesign LLC
  • Magstim EGI
  • Merck KGaA,
  • Natus Medical Inc.
  • NeuroVista Corporation
  • Nexus-DX
  • PhenoSwitch Bioscience
  • Seimens Healthnineers
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43150DF82D01

The Brain Biomarkers Market was valued at USD 8.94 billion in 2023, expected to reach USD 10.54 billion in 2024, and is projected to grow at a CAGR of 17.90%, to USD 28.33 billion by 2030.

Brain biomarkers are measurable indicators of biological processes within the brain, often used for assessing neurological conditions. They are vital for diagnosing and monitoring diseases like Alzheimer's, Parkinson's, and various psychiatric disorders. These biomarkers range from genetic and proteomic to imaging and physiological signals. The necessity of brain biomarkers lies in their ability to facilitate early diagnosis, track disease progression, and tailor personalized treatment plans, significantly improving patient outcomes and healthcare efficiency.

KEY MARKET STATISTICS
Base Year [2023] USD 8.94 billion
Estimated Year [2024] USD 10.54 billion
Forecast Year [2030] USD 28.33 billion
CAGR (%) 17.90%

The application of brain biomarkers spans diagnostics, drug development, and therapeutic monitoring. They are employed in hospitals, research institutes, and clinical labs, serving neurologists, psychiatrists, and other healthcare professionals. The market for brain biomarkers is bolstered by increasing prevalence of neurological disorders, growing demand for personalized medicine, and advances in biomarker technologies. Emerging opportunities include the integration of AI and machine learning to enhance biomarker discovery and analysis, as well as the exploration of biomarkers in the mental health domain.

Key growth factors include technological advancements in neuroimaging and genomics, rising awareness about brain health, and increasing investments in precision medicine. However, challenges such as the high cost of biomarker discovery and validation, regulatory complexities, and limited availability of longitudinal data pose significant hurdles. Moreover, ethical considerations related to genetic testing and data privacy could impact market dynamics.

Innovative areas ripe for exploration include multi-omics approaches to detect composite biomarkers, development of non-invasive biomarker detection methods, and collaborations between biotech firms and research institutions for accelerated R&D. A deeper focus on personalized health approaches, integrating patient-specific data to refine predictive models, holds promise for market expansion.

In conclusion, the brain biomarker market is primed for growth, driven by technological advancements and healthcare demand. Addressing challenges requires strategic investments in research, cross-disciplinary collaborations, and robust regulatory frameworks to navigate ethical and technical landscapes while capitalizing on emerging opportunities for market innovation and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Biomarkers Market

The Brain Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
    • Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
    • Detection and interpretation to support clinical decisions and patient interventions
  • Market Restraints
    • Lack of consumer awareness
  • Market Opportunities
    • Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
    • Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
  • Market Challenges
    • Complexity of neuroinflammation exacerbated by substantial biological heterogeneity

Porter's Five Forces: A Strategic Tool for Navigating the Brain Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Biomarkers Market

A detailed market share analysis in the Brain Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Biomarkers Market

A strategic analysis of the Brain Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Advanced Brain Monitoring, Inc, Biognosys AG, BrainScope Company, Inc., F. Hoffmann-La Roche AG, GE Healthcare, Johnson & Johnson, Lifesign LLC, Magstim EGI, Merck KGaA,, Natus Medical Inc., NeuroVista Corporation, Nexus-DX, PhenoSwitch Bioscience, Seimens Healthnineers, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biomarker Analyzers and Biomarker Test Kits.
  • Based on Indication, market is studied across Alzheimer's Disease, Huntington's Disease, MND & ALS, Parkinson's Disease, and Stroke.
  • Based on End-Users, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, Hospitals, and Research Laboratories.
  • Based on Application, market is studied across Diagnosis and Drug Discovery & Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
      • 5.1.1.2. Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
      • 5.1.1.3. Detection and interpretation to support clinical decisions and patient interventions
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of consumer awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
      • 5.1.3.2. Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of neuroinflammation exacerbated by substantial biological heterogeneity
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Biomarkers Market, by Product

  • 6.1. Introduction
  • 6.2. Biomarker Analyzers
  • 6.3. Biomarker Test Kits

7. Brain Biomarkers Market, by Indication

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Huntington's Disease
  • 7.4. MND & ALS
  • 7.5. Parkinson's Disease
  • 7.6. Stroke

8. Brain Biomarkers Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Diagnostic Laboratories
  • 8.4. Hospitals
  • 8.5. Research Laboratories

9. Brain Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnosis
  • 9.3. Drug Discovery & Development

10. Americas Brain Biomarkers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Brain Biomarkers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Brain Biomarkers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advanced Brain Monitoring, Inc
  • 2. Biognosys AG
  • 3. BrainScope Company, Inc.
  • 4. F. Hoffmann-La Roche AG
  • 5. GE Healthcare
  • 6. Johnson & Johnson
  • 7. Lifesign LLC
  • 8. Magstim EGI
  • 9. Merck KGaA,
  • 10. Natus Medical Inc.
  • 11. NeuroVista Corporation
  • 12. Nexus-DX
  • 13. PhenoSwitch Bioscience
  • 14. Seimens Healthnineers
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TEST KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MND & ALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023